CN117925457A - Lactic acid bacteria composition and application thereof - Google Patents
Lactic acid bacteria composition and application thereof Download PDFInfo
- Publication number
- CN117925457A CN117925457A CN202410038376.5A CN202410038376A CN117925457A CN 117925457 A CN117925457 A CN 117925457A CN 202410038376 A CN202410038376 A CN 202410038376A CN 117925457 A CN117925457 A CN 117925457A
- Authority
- CN
- China
- Prior art keywords
- lactic acid
- acid bacteria
- composition
- strains
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 119
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims description 124
- 241000894006 Bacteria Species 0.000 title claims description 62
- 235000014655 lactic acid Nutrition 0.000 title claims description 62
- 239000004310 lactic acid Substances 0.000 title claims description 62
- 231100000678 Mycotoxin Toxicity 0.000 claims abstract description 23
- 239000002636 mycotoxin Substances 0.000 claims abstract description 23
- 241000191998 Pediococcus acidilactici Species 0.000 claims abstract description 18
- 239000006041 probiotic Substances 0.000 claims abstract description 17
- 235000018291 probiotics Nutrition 0.000 claims abstract description 17
- 241000191996 Pediococcus pentosaceus Species 0.000 claims abstract description 12
- 241001106597 Enterococcus lactis Species 0.000 claims abstract description 5
- 239000007858 starting material Substances 0.000 claims abstract description 4
- 238000004321 preservation Methods 0.000 claims description 29
- 238000000855 fermentation Methods 0.000 claims description 15
- 230000004151 fermentation Effects 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 10
- 241000194033 Enterococcus Species 0.000 claims description 6
- 230000000529 probiotic effect Effects 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 239000002738 chelating agent Substances 0.000 claims description 3
- 230000000593 degrading effect Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 239000002270 dispersing agent Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 239000003349 gelling agent Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 239000013049 sediment Substances 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 abstract description 42
- 229940039696 lactobacillus Drugs 0.000 abstract description 42
- 230000015556 catabolic process Effects 0.000 abstract description 36
- 238000006731 degradation reaction Methods 0.000 abstract description 36
- 230000012010 growth Effects 0.000 abstract description 15
- 239000002253 acid Substances 0.000 abstract description 10
- 239000003833 bile salt Substances 0.000 abstract description 10
- 244000005700 microbiome Species 0.000 abstract description 3
- 241000192001 Pediococcus Species 0.000 abstract 1
- 239000003053 toxin Substances 0.000 description 23
- 231100000765 toxin Toxicity 0.000 description 22
- 108700012359 toxins Proteins 0.000 description 22
- MBMQEIFVQACCCH-QBODLPLBSA-N zearalenone Chemical compound O=C1O[C@@H](C)CCCC(=O)CCC\C=C\C2=CC(O)=CC(O)=C21 MBMQEIFVQACCCH-QBODLPLBSA-N 0.000 description 20
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 18
- 229930020125 aflatoxin-B1 Natural products 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 10
- 206010018910 Haemolysis Diseases 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 238000012258 culturing Methods 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000008588 hemolysis Effects 0.000 description 7
- 238000009630 liquid culture Methods 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 6
- -1 DON Chemical compound 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 229930182566 Gentamicin Natural products 0.000 description 5
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 241000607142 Salmonella Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 239000004098 Tetracycline Substances 0.000 description 5
- 238000001784 detoxification Methods 0.000 description 5
- 229960003276 erythromycin Drugs 0.000 description 5
- 229960002518 gentamicin Drugs 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 235000019364 tetracycline Nutrition 0.000 description 5
- 150000003522 tetracyclines Chemical class 0.000 description 5
- 108010093965 Polymyxin B Proteins 0.000 description 4
- 229960003405 ciprofloxacin Drugs 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920000024 polymyxin B Polymers 0.000 description 4
- 229960005266 polymyxin b Drugs 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- 210000004767 rumen Anatomy 0.000 description 3
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 2
- 241000223218 Fusarium Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 2
- LINOMUASTDIRTM-QGRHZQQGSA-N deoxynivalenol Chemical compound C([C@@]12[C@@]3(C[C@@H](O)[C@H]1O[C@@H]1C=C(C([C@@H](O)[C@@]13CO)=O)C)C)O2 LINOMUASTDIRTM-QGRHZQQGSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 230000015784 hyperosmotic salinity response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960001699 ofloxacin Drugs 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- LINOMUASTDIRTM-UHFFFAOYSA-N vomitoxin hydrate Natural products OCC12C(O)C(=O)C(C)=CC1OC1C(O)CC2(C)C11CO1 LINOMUASTDIRTM-UHFFFAOYSA-N 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010057648 Cyclopia Diseases 0.000 description 1
- 241001219085 Cyclopia Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- BXFOFFBJRFZBQZ-QYWOHJEZSA-N T-2 toxin Chemical compound C([C@@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@H]1[C@]3(COC(C)=O)C[C@@H](C(=C1)C)OC(=O)CC(C)C)O2 BXFOFFBJRFZBQZ-QYWOHJEZSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002053 acidogenic effect Effects 0.000 description 1
- 239000002115 aflatoxin B1 Substances 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000433 anti-nutritional effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229930002954 deoxynivalenol Natural products 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- UVBUBMSSQKOIBE-DSLOAKGESA-N fumonisin B1 Chemical compound OC(=O)C[C@@H](C(O)=O)CC(=O)O[C@H]([C@H](C)CCCC)[C@@H](OC(=O)C[C@@H](CC(O)=O)C(O)=O)C[C@@H](C)C[C@H](O)CCCC[C@@H](O)C[C@H](O)[C@H](C)N UVBUBMSSQKOIBE-DSLOAKGESA-N 0.000 description 1
- QZIADBYRQILELJ-UHFFFAOYSA-N fumonisin B1 Natural products CCCCC(C)C(OC(=O)CC(CC(=O)O)C(=O)O)C(C)(CC(C)CC(O)CCCCC(O)CC(O)C(C)N)OC(=O)CC(CC(=O)O)C(=O)O QZIADBYRQILELJ-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229930183344 ochratoxin Natural products 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- WQVJHHACXVLGBL-GOVYWFKWSA-N polymyxin B1 Polymers N1C(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)CCCC[C@H](C)CC)CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1CC1=CC=CC=C1 WQVJHHACXVLGBL-GOVYWFKWSA-N 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000462 teratogen Toxicity 0.000 description 1
- 239000003439 teratogenic agent Substances 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- MBMQEIFVQACCCH-UHFFFAOYSA-N trans-Zearalenon Natural products O=C1OC(C)CCCC(=O)CCCC=CC2=CC(O)=CC(O)=C21 MBMQEIFVQACCCH-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of microorganisms, in particular to a lactobacillus composition and application thereof. The composition comprises at least two of the following strains: pediococcus acidilactici ACIDILACTICI H, pediococcus pentosaceus Pediococcuspentosaceus HZ, pediococcus lactici Enterococcus lactis H, pediococcus acidilactici Lactiplantibacilluspentosus HZ. The lactobacillus composition is used for preparing a feed starter. The invention has the advantages that: (1) high-efficiency degradation of mycotoxin. (2) strong growth capacity, acid resistance and bile salt resistance. (3) safe and has better probiotics.
Description
Technical Field
The invention relates to the technical field of microorganisms, in particular to a lactobacillus composition and application thereof.
Background
The feed and the raw materials thereof are easy to mildew and generate mould in the process of processing, storing and transporting. The mould not only reduces the nutritive value of the feed and affects the palatability, resulting in the reduction of the feed intake of livestock and poultry, but also causes the growth arrest of animals, the reduction of immunity, the reduction of production performance and even poisoning and death.
Among the mycotoxins commonly found in daily life are AFB1, ZEA, DON, T-2 toxin (T-2), ochratoxin (OTA), fumonisin B1 (FB 1), cyclopia aninic acid (CPA), and the like. The source, physiological response and clinical symptoms of different mycotoxins are all different: wherein the AFB1 is derived from Aspergillus flavus, and can damage animal liver, inhibit immunity, and cause cancer and death of animals and human after long-term exposure. ZEA is an estrogenic toxin produced by Fusarium, and poisoning is manifested by reduced feed conversion rate, organ weight change, reduced animal fertility, abnormal behavior, etc. DON and T-2 are derived from Fusarium, respectively type B and type A, and can directly damage animal digestive tract mucosa, and are generally manifested by anorexia, hemorrhage, emesis, diarrhea, etc. OTA is derived from Aspergillus and Penicillium, and is an immunosuppressant, teratogen and nephrotoxic compound, and poisoning can cause renal cortex degeneration, medullary hemorrhage and other diseases, and the target organ is kidney.
Mycotoxin is used as an anti-nutritional factor, has hepatotoxicity, mutagenicity, nephrotoxicity, immunosuppression and carcinogenesis, is widely polluted in grains, agricultural and sideline products and traditional Chinese medicinal materials, and is one of the important means for removing mycotoxin at present by utilizing microorganisms to convert the toxin into non-toxic or low-toxic metabolites.
Most of the lactic acid bacteria which have been found to degrade only one toxin have been less studied for lactic acid bacteria which degrade a plurality of toxins simultaneously.
Disclosure of Invention
The invention aims to provide a lactobacillus composition which can simultaneously and efficiently degrade various mycotoxins, has the advantages of probiotics, strong growth capacity, acid resistance, bile salt resistance and no hemolysis, and application thereof.
Preservation description:
1. Classification naming: pediococcus ACIDILACTICI H47,47;
Preservation time: 2023, 11, 08;
Preservation unit: china center for type culture Collection; preservation address: no. 299 of eight paths in Wuhan City of Hubei province in Wuchang district
Preservation number: cctccc NO: m20232100.
2. Classification naming: pediococcuspentosaceus HZ44 and 44;
Preservation time: 2023, 11, 08;
Preservation unit: china center for type culture Collection; preservation address: no. 299 of eight paths in Wuhan City of Hubei province in Wuchang district
Preservation number: cctccc NO: m20232101.
3. Classification naming: enterococcus lactis H49,49;
Preservation time: 2023, 11, 08;
Preservation unit: china center for type culture Collection; preservation address: no. 299 of eight paths in Wuhan City of Hubei province in Wuchang district
Preservation number: cctccc NO: m20232102.
4. Classification naming: lactiplantibacilluspentosus HZ49,49;
Preservation time: 2023, 11, 08;
Preservation unit: china center for type culture Collection; preservation address: no. 299 of eight paths in Wuhan City of Hubei province in Wuchang district
Preservation number: cctccc NO: m20232103.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
in a first aspect, the present invention provides a lactic acid bacteria composition.
A lactic acid bacteria composition comprising at least two of the following strains:
The preservation number is CCTCC NO: pediococcus acidilactici H47 (Pediococcus ACIDILACTICI H) of M20232100,
The preservation number is CCTCC NO: m20232101 Pediococcus pentosaceus HZ44 (Pediococcus pentosaceus HZ) 44,
The preservation number is CCTCC NO: M20232102A enterococcus strain H49 (Enterococcus lactis H) and,
The preservation number is CCTCC NO: pediococcus acidilactici HZ49 (Lactiplantibacillus pentosus HZ) of M20232103.
Further, the composition comprises 4 of the strains.
Further, the composition comprises Pediococcus acidilactici H47, pediococcus pentosaceus HZ44, enterococcus strain H49 and Pediococcus acidilactici HZ49 in a ratio of 1:1:1:1.
Further, the composition is a fermentation broth, a fermentation precipitate or a freeze-dried powder.
Further, the composition is a microecological preparation or a pharmaceutical preparation.
Further, the composition comprises a carrier.
Further, the carrier includes, but is not limited to, the following components: solvents, buffers, emulsifiers, suspending agents, disintegrants, dispersants, binders, excipients, stabilizers, chelating agents, diluents, gelling agents, wetting agents, other probiotics, and combinations thereof.
In a second aspect, the present invention provides a use of a lactic acid bacteria composition.
The use of said lactic acid bacteria composition for the preparation of a composition for degrading mycotoxins.
In a third aspect, the invention provides another use of a lactic acid bacteria composition.
Use of the lactic acid bacteria composition for the preparation of a composition for use in a probiotic.
In a fourth aspect, the present invention provides the use of a lactic acid bacteria composition.
The lactobacillus composition is used for preparing a feed starter.
The lactobacillus composition provided by the invention can contain other probiotics, and the probiotics can be selected from: any one or combination of lactobacillus, bifidobacterium and lactobacillus acidophilus.
The composition of Pediococcus pentosaceus provided by the invention can contain prebiotics, wherein the prebiotics can be any one or a combination of fructo-oligosaccharide (FOS), galacto-oligosaccharide (GOS), xylo-oligosaccharide (XOS), lactulose-oligosaccharide (LACT), soybean Oligosaccharide (SOS), inulin (Inulin) and oligosaccharide.
The four strains in the lactobacillus composition provided by the invention are all isolated from the rumen of Qinghai-Tibetan sheep. The lactobacillus composition can efficiently degrade mycotoxin and has probiotic characteristics; can be used as feed additive or strain fermented feed, and can improve feed utilization rate.
The lactic acid bacteria composition provided by the invention can efficiently degrade mycotoxin, and the degradation rates of AFB1 (Aaflatoxin B, aflatoxin B1), DON (Deoxynivalenol, vomitoxin), ZEA (Zealaenone, zearalenone) and GLUS (thioglucoside) are respectively 89.89%, 79.40%, 57.63% and 88.95%. The average degradation rate for AFB1, DON, ZEA and GLUS was 78.96%.
The lactic acid bacteria composition provided by the invention has the advantages of shortest fermentation time, stronger environmental adaptability and stronger vitality. Can grow normally in an acidic environment with pH of 3.5, and has complete tolerance to 0.1 percent of bile salt environment and high acid and bile salt tolerance. Is completely tolerant to 2.0% NaCl concentration.
The lactobacillus composition provided by the invention has no hemolysis symptom. Strains H47, HZ49 were moderately sensitive to erythromycin, and both strains H49 and HZ44 were highly sensitive. Strains H47, HZ44, H49 and HZ49 were all insensitive to streptomycin and gentamicin. H49, HZ44 and HZ49 were highly sensitive to penicillin and strain H47 was moderately sensitive. Strain HZ44 is highly sensitive to tetracycline and strains H47, HZ49 and H49 are insensitive. Strains H47, HZ44 and HZ49 are all insensitive to polymyxin B and H47 is moderately sensitive. Strains H47, HZ44, H49 and HZ49 were all insensitive to ciprofloxacin. Strains H47, HZ44, H49 and HZ49 show a certain inhibition effect on salmonella, escherichia coli and staphylococcus aureus. The strain is safe and has good probiotics.
The lactobacillus composition which can efficiently degrade mycotoxin and has probiotics is separated and screened from rumen of Qinghai-Tibetan sheep, and the lactobacillus composition ferments the feed, so that the lactobacillus composition can degrade various mycotoxins in feed raw materials simultaneously, improves the safety of the feed, can increase the utilization of some unconventional feed raw materials, and has great prospect in the application of fermented feed taking unconventional feed as raw materials.
Compared with the prior art, the lactic acid bacteria composition and the application thereof provided by the invention have the advantages that:
(1) And the mycotoxin is efficiently degraded.
(2) Strong growth ability, acid resistance and bile salt resistance.
(3) Safe and has good probiotic property.
Drawings
FIG. 1 is a graph showing the growth curves of 4 strains in the lactic acid bacteria composition provided by the invention.
FIG. 2 shows the acid production curves of 4 strains in the lactic acid bacteria composition provided by the invention.
FIG. 3 shows the growth of 4 strains of the lactic acid bacteria composition according to the present invention under different pH conditions.
FIG. 4 shows growth of 4 strains in lactic acid bacteria compositions according to the present invention under different bile salt concentrations.
FIG. 5 shows growth of 4 strains in the lactic acid bacteria composition of the present invention at different concentrations of NaCl.
FIG. 6 shows the results of hemolysis test of 4 strains in the lactic acid bacteria composition provided by the present invention.
FIG. 7 shows detoxification curves of 4 strains of the lactic acid bacteria composition according to the present invention against AFB 1.
FIG. 8 shows the detoxification curves of 4 strains against DON in the lactic acid bacteria composition provided by the present invention.
FIG. 9 shows detoxification curves of 4 strains of ZEA in lactic acid bacteria compositions provided by the present invention.
FIG. 10 shows detoxification curves of 4 strains of GLUS in a lactic acid bacteria composition according to the present invention.
FIG. 11 shows the mycotoxin content change during fermentation of 4 strains in the lactic acid bacteria composition provided by the invention.
In fig. 11, G14 is the lactic acid bacteria composition provided by the present invention.
Detailed Description
The following examples are given for the purpose of illustration only and are not intended to limit the scope of the invention in order to provide a better understanding of the technical solution of the present invention to those skilled in the art.
In a first aspect, the present invention provides a lactic acid bacteria composition.
A lactic acid bacteria composition comprising at least two of the following strains:
The preservation number is CCTCC NO: pediococcus acidilactici H47 (Pediococcus ACIDILACTICI H) of M20232100,
The preservation number is CCTCC NO: m20232101 Pediococcus pentosaceus HZ44 (Pediococcus pentosaceus HZ) 44,
The preservation number is CCTCC NO: M20232102A enterococcus strain H49 (Enterococcus lactis H) and,
The preservation number is CCTCC NO: pediococcus acidilactici HZ49 (Lactiplantibacillus pentosus HZ) of M20232103.
Further, the composition comprises 4 of the strains.
Further, the composition comprises Pediococcus acidilactici H47, pediococcus pentosaceus HZ44, enterococcus strain H49 and Pediococcus acidilactici HZ49 in a ratio of 1:1:1:1.
Further, the composition is a fermentation broth, a fermentation precipitate or a freeze-dried powder.
Further, the composition is a microecological preparation or a pharmaceutical preparation.
Further, the composition comprises a carrier.
Further, the carrier includes, but is not limited to, the following components: solvents, buffers, emulsifiers, suspending agents, disintegrants, dispersants, binders, excipients, stabilizers, chelating agents, diluents, gelling agents, wetting agents, other probiotics, and combinations thereof.
In a second aspect, the present invention provides a use of a lactic acid bacteria composition.
The use of said lactic acid bacteria composition for the preparation of a composition for degrading mycotoxins.
In a third aspect, the invention provides another use of a lactic acid bacteria composition.
Use of the lactic acid bacteria composition for the preparation of a composition for use in a probiotic.
In a fourth aspect, the present invention provides the use of a lactic acid bacteria composition.
The lactobacillus composition is used for preparing a feed starter.
Example 1
Probiotic properties of lactic acid bacteria compositions
1. Determination of growth Capacity and acid production Capacity
Inoculating lactobacillus composition bacterial liquid into MRS liquid culture medium according to 3% inoculum size, culturing at 37 ℃ at constant temperature, and drawing growth curve and acidogenic curve respectively at 0h, 2h, 4h, 6h, 8h, 12h, 16h, 24h, 36h and 48h, 3 repeats each group, measuring OD 600 value and pH value by taking blank culture medium as reference, and culturing time of bacterial liquid as horizontal coordinate and absorbance value and pH value as vertical coordinate.
As shown in the growth curve of FIG. 1, all strains are in a slow period between 0 and 4 hours, except that the strain HZ44 enters the logarithmic growth phase after being inoculated for 6 hours, the other strains enter the logarithmic growth phase after being inoculated for 4 hours, so that the fermentation time is short, the environmental adaptability is strong, and the vitality is vigorous; the OD 600 value is 1.5-2.0 in the stable period of 24-48h, and the fermentation activity is stronger.
As shown in the acid-producing curve of fig. 2, the change trend of the pH of 4 lactic acid bacteria is almost consistent, the pH gradually goes to the stable phase from the stable state to the rapid decrease phase, when the strain goes to the logarithmic phase, the pH of the culture medium starts to decrease, and after the strain grows to the stable phase, the pH starts to stabilize again. All strains rapidly decreased in pH after entering the logarithmic growth phase; all strains enter the stable period in 24 hours, and the pH value at 48 hours can reach below 4.5, which shows that the acid production performance is best.
2. Acid and bile salt tolerance
Inoculating lactobacillus composition bacterial liquid into MRS liquid culture mediums with pH values of 2.5, 3.0, 3.5, 4.0 and 6.0 according to 1% inoculum size, culturing at 37 ℃ for 24 hours, and measuring OD 600 value of the bacterial liquid; inoculating into MRS liquid culture medium with 0.0%, 0.1%, 0.2% and 0.3% of ox gall salt concentration according to 1% inoculum size, culturing for 24 hr, respectively measuring OD 600 value of bacterial liquid, and using blank culture medium with same acidity and gall salt concentration as control.
As shown in FIG. 3, 4 strains in the lactobacillus composition can grow basically normally in an acidic environment with pH of 3.5 and pH of 4.0, wherein the growth rate of the strain H47 is faster than that of other strains; the 4 strains were essentially intolerant to the acidic environments at pH3.0 and pH2.5, essentially arresting growth.
As shown in fig. 4,4 strains in the lactic acid bacteria composition were completely tolerant to 0.1% bile salt environment, with strain H47 being the best; under the condition of 0.2% of bile salt, the growth of 4 strains of lactic acid bacteria is severely inhibited, wherein the strain H47 has the best tolerance performance; other strains than H47 were essentially arrested in growth at 0.3% bile salts.
3. Osmotic pressure resistance
2.0%, 4.0%, 6.0% And 8.0% NaCl are respectively added into an MRS liquid culture medium, the lactobacillus composition bacterial liquid is inoculated into the MRS liquid culture medium with different NaCl concentrations according to 1% inoculum size, after the temperature is kept at 37 ℃ for 24 hours, the OD 600 value of each group bacterial liquid is respectively measured, and 3 replicates of each group are used as a control, and a blank culture medium with the same NaCl concentration is used as a control.
As shown in FIG. 5, 4 strains in the lactic acid bacteria composition were completely tolerant to 2.0% NaCl concentration, the OD value was slowly decreased at 4.0% NaCl concentration, and each strain was inhibited in an environment of more than 6.0% NaCl.
4. Safety inspection
(1) Lactic acid bacteria hemolysis test
All screened strains were streaked on Columbia platelets and incubated for 24-48 h. The presence or absence of a hemolytic loop around the colonies was observed: alpha-hemolysis, beta-hemolysis and gamma-hemolysis, and recorded by photographing.
As shown in fig. 6, 4 strains in the lactic acid bacteria composition did not show hemolysis symptom (γ hemolysis) after 48 hours of incubation.
(2) Lactic acid bacteria antibiotic susceptibility test
The drug sensitivity test of 8 antibiotics is carried out on 4 strains respectively by using a drug sensitivity paper sheet method. Polymyxin B (Polymycin B, PB); ciprofloxacin (Ciorofloxacin, CIP); tetracyclines (TETRACYCLINE, TE); gentamicin (GENTAMICIN, GEN); erythromycin (Erythromycin, E); ofloxacin (Ofloxacin, OFX); penicillin (Penicillin, P); streptomycin (streptomycin, S).
Of the 4 strains in the lactic acid bacteria composition, strains H47 and HZ49 were moderately sensitive to erythromycin, and strains H49 and HZ44 were both highly sensitive. The 4 strains are insensitive to streptomycin and gentamicin. Strains H49, HZ44 and HZ49 were highly sensitive to penicillin and strain H47 was moderately sensitive. Strain HZ44 is highly sensitive to tetracycline and the remaining strains are insensitive. Strains H47, HZ44 and HZ49 were all insensitive to polymyxin B and strain H49 was moderately sensitive. The 4 strains are insensitive to ciprofloxacin.
(3) Determination of bacteriostasis of lactic acid bacteria
The diameter of the inhibition zone of the strain fermentation supernatant to pathogenic bacteria such as escherichia coli, salmonella, staphylococcus aureus and the like is measured by adopting an oxford cup method.
As shown in Table 4, among 4 strains in the lactic acid bacteria composition, H47 and HZ49 had strong antibacterial properties against Salmonella, and H49 and HZ44 had antibacterial properties against Salmonella. H47, HZ44 and HZ49 have strong antibacterial performance on escherichia coli, and H49 has antibacterial performance on escherichia coli. H47 and HZ49 have extremely strong antibacterial performance on staphylococcus aureus, and H49 and HZ44 have relatively strong antibacterial performance on staphylococcus aureus.
TABLE 4 antibacterial results of lactic acid bacteria
"+" Indicates that the diameter of the inhibition zone is 9.0-12.99 mm; "++" indicates that the diameter of the inhibition zone is 13.0-16.99 mm; "++ + +" indicates that the diameter of the inhibition zone is 17.0-19.99 mm; "+". ++'s indicating bacteriostasis the diameter of the ring is more than or equal to 20mm.
Example 2
Individual degradation of mycotoxins by lactic acid bacteria compositions
1. Mycotoxin degradation rate test
The degradation effect of the lactobacillus composition on AFB1, DON, ZEA and GLUS was tested, and the degradation rate of 4 mycotoxins was determined after 72h fermentation. The results are shown in Table 5.
As can be seen from Table 5, the degradation rate of the tested lactic acid bacteria compositions on AFB1, DON and GLUS was above 80% when the four toxins were present alone. The degradation rate of the lactobacillus composition on AFB1 is 91.53 percent and the degradation rate on DON is 85.24 percent; the degradation rate of ZEA is 64.45%; the degradation rate of GLUS is 93.13%.
When four toxins were present alone, the degradation rate of the lactobacillus composition was tested for AFB1, DON and GLUS, all at 80% or more.
TABLE 5 degradation rates of lactic acid bacteria compositions on four toxins
2. Detoxification curve of lactic acid bacteria composition
Inoculating lactobacillus composition into MRS liquid culture medium according to 1%, culturing at 37deg.C for 24 hr, culturing with four toxins respectively, measuring toxin content at 0 hr, 2 hr, 4 hr, 8 hr, 12 hr, 1d, 3d, 7d, and 14d time periods, drawing detoxication curve with culturing time as abscissa and degradation rate as ordinate, and analyzing toxin degradation rate variation at different time periods.
As shown in fig. 7 to 10, the degradation rates of the lactobacillus composition for all four toxins increase with time, and the degradation rate for AFB1 changes as follows: slowly rises before 12h, rapidly rises after 12h, and gradually reaches a stable stage after 7 d. The degradation rate change trend of DON is as follows: slowly rises before 12h, and gradually goes to a stable stage after 12 h. The degradation rate change trend of the ZEA is as follows: slowly rises in 2-12 h, and the degradation rate rapidly rises in 12-24 h. The degradation rate change trend of GLUS is as follows: slowly rises in 2-12 h, and the degradation rate rapidly rises in 12-24 h.
In summary, the higher the degradation rate of the lactic acid bacteria composition to AFB1, DON, ZEA and GLUS with increasing fermentation time.
Example 3
Degradation of 4 mycotoxins by lactic acid bacteria composition
Inoculating lactobacillus composition into MRS liquid culture medium, culturing at 37deg.C for 24 hr, co-culturing with toxins, respectively measuring the toxin content in sample when four toxins exist alone and simultaneously, calculating toxin degradation rate, and determining optimal combination.
The lactobacillus composition has certain degradation capability to four toxins, and the degradation rate of the four toxins existing simultaneously is lower than that of the four toxins existing independently. When four toxins are present alone, the degradation rates of AFB1, DON and GLUS are all above 80%.
When the four toxins exist simultaneously, the degradation rate of the lactobacillus composition on AFB1 and GLUS is more than 80 percent, and the degradation rate on DON is more than 70 percent. The degradation rate to ZEA is more than 50%. The degradation rate of toxin is as follows: AFB1 is more than GLUS and DON is more than ZEA, and the degradation rate of the lactobacillus composition to AFB1 and DON, ZEA, GLUS is 88.95 percent at most.
Example 4
Composite probiotics fermented feed
Fermenting the moldy feed with the lactobacillus composition, accurately weighing 500g of uniformly stirred feed, fermenting the feed according to the inoculation amount (bacterial liquid: feed) of 5% and the water-material ratio (water: feed) of 70%, after uniformly mixing the feed, subpackaging into 500g of fermentation bags, sealing by a vacuum sealing machine, and fermenting at 37 ℃. The experimental treatment was designed as follows: (1) control group (CK); (2) Test group (Z4), three replicates of each treatment group, samples were collected over 0, 1, 3, 5, 7, 10 and 15 days, respectively, giving a total of 42 samples. After sampling, the sample was stored at-80℃and analyzed in the next step.
The mycotoxins varied during the fermentation of the feed are shown in figure 11, and the three other toxins, except DON, all had a decreasing trend over time. Compared to the control group, the lactobacillus composition had lower levels of AFB1, DON, ZEA and GLUS than the control group.
As shown in FIG. 11-A, the AFB1 content of the lactobacillus composition rapidly decreases before 3d, slowly decreases after 3d, is significantly lower than that of the control group (P < 0.05) at 3d, is significantly lower than that of the control group (P < 0.01) at 1, 7 and 10d, and reaches the lowest content of 2.60ppb at 3d, which is reduced by 50.73%.
Variation of DON content As shown in FIG. 11-B, the DON content of the lactobacillus composition was significantly lower in 1d than in the control group (P < 0.05), and the DON content in 3, 5, 7, 10, 15d was significantly lower in the control group (P < 0.01), so that the DON content in the lactobacillus composition was reduced by 50.70% in 15 d.
As shown in FIG. 11-C, the ZEA content of the lactobacillus composition increases from 0 to 1d, the ZEA content of the lactobacillus composition slightly increases after 7d, the ZEA content of the lactobacillus composition is obviously lower than that of a control group (P < 0.05) in the 3 rd and 10d stages, the ZEA content of the lactobacillus composition is obviously lower than that of the control group (P < 0.01) in the 1 st, 5 th, 7 th and 15d stages, the minimum ZEA content of the lactobacillus composition reaches 21.29ppb in the 7d stage, and the reduction of 85.90%.
The change in GLUS content as shown in FIG. 11-D shows that the GLUS content of the lactic acid bacteria composition group was significantly lower than that of the control group (P < 0.05) at 3D, and there was no difference in other time periods, the content was the lowest at 15D,
The results show that the degradation efficiency of the compound probiotics on mycotoxins is better than that of single strains, and the degradation rate of the lactobacillus composition of the strains H47, HZ44, H49 and HZ49 on AFB1 and DON, ZEA, GLUS is 89.89%, 79.40%, 57.63% and 88.95%.
The lactobacillus composition provided by the invention has no hemolysis symptom. Strains H47, HZ49 were moderately sensitive to erythromycin, and both strains H49 and HZ44 were highly sensitive. Strains H47, HZ44, H49 and HZ49 were all insensitive to streptomycin and gentamicin. H49, HZ44 and HZ49 were highly sensitive to penicillin and strain H47 was moderately sensitive. Strain HZ44 is highly sensitive to tetracycline and strains H47, HZ49 and H49 are insensitive. Strains H47, HZ44 and HZ49 are all insensitive to polymyxin B and H47 is moderately sensitive. Strains H47, HZ44, H49 and HZ49 were all insensitive to ciprofloxacin. Strains H47, HZ44, H49 and HZ49 show a certain inhibition effect on salmonella, escherichia coli and staphylococcus aureus. The strain is safe and has good probiotics.
The lactobacillus composition which can efficiently degrade mycotoxin and has probiotics is separated and screened from rumen of Qinghai-Tibetan sheep, and the lactobacillus composition ferments the feed, so that the lactobacillus composition can degrade various mycotoxins in feed raw materials simultaneously, improves the safety of the feed, can increase the utilization of some unconventional feed raw materials, and has great prospect in the application of fermented feed taking unconventional feed as raw materials.
The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the specific details of the above embodiments, and various modifications can be made to the technical solutions of the present invention within the scope of the technical concept of the present invention, and these simple modifications all fall within the scope of the present invention.
In addition, the specific features and steps described in the foregoing embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various possible combinations are not described in detail.
Moreover, any combination of the various embodiments of the invention can be made without departing from the spirit of the invention, which should also be considered as disclosed herein.
Claims (10)
1. A lactic acid bacteria composition, characterized in that said composition comprises at least two of the following strains:
The preservation number is CCTCC NO: pediococcus acidilactici H47 (Pediococcus ACIDILACTICI H) of M20232100,
The preservation number is CCTCC NO: m20232101 Pediococcus pentosaceus HZ44 (Pediococcus pentosaceus HZ) 44,
The preservation number is CCTCC NO: M20232102A enterococcus strain H49 (Enterococcus lactis H) and,
The preservation number is CCTCC NO: pediococcus acidilactici HZ49 (Lactiplantibacillus pentosus HZ) of M20232103.
2. The lactic acid bacteria composition according to claim 1, characterized in that: the composition comprises 4 of the strains.
3. The lactic acid bacteria composition according to claim 1, characterized in that: the ratio of Pediococcus acidilactici H47, pediococcus pentosaceus HZ44, enterococcus lactici strain H49 and Pediococcus acidilactici HZ49 in the composition is 1:1:1:1w/w.
4. The lactic acid bacteria composition according to claim 1, characterized in that: the composition is fermentation liquor, fermentation sediment or freeze-dried powder.
5. The lactic acid bacteria composition according to claim 1, characterized in that: the composition is a microecological preparation or a pharmaceutical preparation.
6. The lactic acid bacteria composition according to claim 1, characterized in that: the composition comprises a carrier.
7. The lactic acid bacteria composition according to claim 6, characterized in that: the carrier includes, but is not limited to, the following components: solvents, buffers, emulsifiers, suspending agents, disintegrants, dispersants, binders, excipients, stabilizers, chelating agents, diluents, gelling agents, wetting agents, other probiotics, and combinations thereof.
8. Use of a lactic acid bacteria composition according to claim 1 for the preparation of a composition for degrading mycotoxins.
9. Use of a lactic acid bacteria composition according to claim 1 for the preparation of a composition for use in a probiotic.
10. A lactic acid bacteria composition according to claim 1 for use in the preparation of a feed starter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410038376.5A CN117925457A (en) | 2024-01-10 | 2024-01-10 | Lactic acid bacteria composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410038376.5A CN117925457A (en) | 2024-01-10 | 2024-01-10 | Lactic acid bacteria composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117925457A true CN117925457A (en) | 2024-04-26 |
Family
ID=90750077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410038376.5A Pending CN117925457A (en) | 2024-01-10 | 2024-01-10 | Lactic acid bacteria composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117925457A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118028146A (en) * | 2024-01-10 | 2024-05-14 | 青海大学 | Pediococcus acidilactici, composition containing same and application of composition |
| CN118028145A (en) * | 2024-01-10 | 2024-05-14 | 青海大学 | Enterococcus faecalis, composition containing enterococcus faecalis and application of enterococcus faecalis |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101792726A (en) * | 2010-03-25 | 2010-08-04 | 山东宝来利来生物工程股份有限公司 | Enterococcus faecalis capable of absorbing mycotoxin and application thereof in absorbing mycotoxin |
| CN108570421A (en) * | 2017-03-09 | 2018-09-25 | 北京大北农科技集团股份有限公司 | One lactobacillus plantarum strain and its ensilage fermentation agent |
| CN114085789A (en) * | 2021-11-03 | 2022-02-25 | 中国农业大学 | Pediococcus pentosaceus MA.WTPQJ01 and application thereof |
| CN114698767A (en) * | 2022-06-07 | 2022-07-05 | 山东健源生物科技有限公司 | Biological agent for removing mycotoxin in feed as well as preparation method and application of biological agent |
| CN116024112A (en) * | 2021-10-26 | 2023-04-28 | 河南科技大学 | Pediococcus pentosaceus and microbial inoculum thereof, preparation method and application thereof in degradation of aflatoxin |
| CN117866828A (en) * | 2024-01-10 | 2024-04-12 | 青海大学 | Pediococcus acidilactici, composition containing same and application of composition |
| CN118028146A (en) * | 2024-01-10 | 2024-05-14 | 青海大学 | Pediococcus acidilactici, composition containing same and application of composition |
| CN118028145A (en) * | 2024-01-10 | 2024-05-14 | 青海大学 | Enterococcus faecalis, composition containing enterococcus faecalis and application of enterococcus faecalis |
| CN118086101A (en) * | 2024-01-10 | 2024-05-28 | 青海大学 | Pediococcus pentosaceus, composition containing same and application of composition |
-
2024
- 2024-01-10 CN CN202410038376.5A patent/CN117925457A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101792726A (en) * | 2010-03-25 | 2010-08-04 | 山东宝来利来生物工程股份有限公司 | Enterococcus faecalis capable of absorbing mycotoxin and application thereof in absorbing mycotoxin |
| CN108570421A (en) * | 2017-03-09 | 2018-09-25 | 北京大北农科技集团股份有限公司 | One lactobacillus plantarum strain and its ensilage fermentation agent |
| CN116024112A (en) * | 2021-10-26 | 2023-04-28 | 河南科技大学 | Pediococcus pentosaceus and microbial inoculum thereof, preparation method and application thereof in degradation of aflatoxin |
| CN114085789A (en) * | 2021-11-03 | 2022-02-25 | 中国农业大学 | Pediococcus pentosaceus MA.WTPQJ01 and application thereof |
| CN114698767A (en) * | 2022-06-07 | 2022-07-05 | 山东健源生物科技有限公司 | Biological agent for removing mycotoxin in feed as well as preparation method and application of biological agent |
| CN117866828A (en) * | 2024-01-10 | 2024-04-12 | 青海大学 | Pediococcus acidilactici, composition containing same and application of composition |
| CN118028146A (en) * | 2024-01-10 | 2024-05-14 | 青海大学 | Pediococcus acidilactici, composition containing same and application of composition |
| CN118028145A (en) * | 2024-01-10 | 2024-05-14 | 青海大学 | Enterococcus faecalis, composition containing enterococcus faecalis and application of enterococcus faecalis |
| CN118086101A (en) * | 2024-01-10 | 2024-05-28 | 青海大学 | Pediococcus pentosaceus, composition containing same and application of composition |
Non-Patent Citations (2)
| Title |
|---|
| 姚有莉等: "降解霉菌毒素乳酸菌的筛选及鉴定", 动物营养学报, vol. 36, no. 4, 15 April 2024 (2024-04-15) * |
| 陈亚男;郭伟强;陈翠英;金山;: "3株乳酸片球菌的鉴定及其耐酸耐盐特性和抑菌作用研究", 动物医学进展, no. 07, 7 July 2020 (2020-07-07) * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118028146A (en) * | 2024-01-10 | 2024-05-14 | 青海大学 | Pediococcus acidilactici, composition containing same and application of composition |
| CN118028145A (en) * | 2024-01-10 | 2024-05-14 | 青海大学 | Enterococcus faecalis, composition containing enterococcus faecalis and application of enterococcus faecalis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117925457A (en) | Lactic acid bacteria composition and application thereof | |
| Lan et al. | Impact of two probiotic Lactobacillus strains feeding on fecal lactobacilli and weight gains in chicken | |
| EP1345613B1 (en) | Probiotic compounds derived from lactobacillus casei strain ke01 | |
| CN113604405B (en) | Preparation method and application of enterococcus faecium bacterial agent | |
| CN109234182B (en) | Lactobacillus plantarum ZJUFT34 and application thereof | |
| CN110878269B (en) | Novel lactobacillus plantarum RP1 and application thereof | |
| Wang et al. | Assessment of probiotic properties of Lactobacillus plantarum ZLP001 isolated from gastrointestinal tract of weaning pigs | |
| Wang et al. | Effects of oligosaccharides on the growth and stress tolerance of Lactobacillus plantarum ZLP001 in vitro, and the potential synbiotic effects of L. plantarum ZLP001 and fructo-oligosaccharide in post-weaning piglets | |
| CN113549574B (en) | Bacillus coagulans and application thereof | |
| CN114085789B (en) | Pediococcus pentosaceus MA.WTPQJ01 and application thereof | |
| CN102965316B (en) | Bacteriocin containing class and the feed addictive of Pediococcus acidilactici, premix and batch | |
| KR101381547B1 (en) | Novel Leuconostoc mesenteroides from kimchi with inhibiting activities on pathogenic microorganism and use thereof | |
| CN114480231A (en) | Lactobacillus reuteri for resisting helicobacter pylori infection and application thereof | |
| CN117866828A (en) | Pediococcus acidilactici, composition containing same and application of composition | |
| CN118086101A (en) | Pediococcus pentosaceus, composition containing same and application of composition | |
| CN118028145A (en) | Enterococcus faecalis, composition containing enterococcus faecalis and application of enterococcus faecalis | |
| CN118028146A (en) | Pediococcus acidilactici, composition containing same and application of composition | |
| CN113088468B (en) | Lactobacillus casei Ma. GLRGJ1 and application thereof | |
| EP2521459B1 (en) | Metabolites in animal feed | |
| CN111961623B (en) | Compound lactobacillus preparation and application thereof, compound mildew removing agent and application thereof | |
| CA2520178A1 (en) | Probiotic compounds derived from lactobacillus casei strain ke01 | |
| CN114806944B (en) | Lactobacillus plantarum LP11, fermentation broth thereof, and preparation method and application thereof | |
| CN116478859A (en) | Lactic acid bacteria and microorganism preparation capable of tolerating hypochlorous acid water and application thereof | |
| CN109971667B (en) | Porcine lactobacillus plantarum and application thereof | |
| Mohamedy et al. | Efficacy of organic acids and Kanamycin as feed additives in improving the immune status of broiler chickens infected with Salmonella Typhimurium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |